BrainScope® has launched a new generation of its deep learning platform. The company, known for creating the first FDA-cleared AI/machine learning medical device in neurology, is building on its strong machine learning foundation to provide quicker, objective, and clinically useful insights across several brain health conditions such as concussion, stroke, and early detection of Alzheimer’s disease.
The updated platform incorporates deep learning into BrainScope’s proprietary technology, marking a significant advance in automated EEG interpretation.
The new Large Neural Model (LNM) brings the capabilities of large language models to EEG data, removing the need for specialised quantitative EEG (qEEG) analysis.
This proprietary method enhances the company's existing machine learning tools and opens up wider applications in clinical practice, research, and biopharmaceuticals.
It is designed to support the development of more accurate biomarkers for improved clinical trial recruitment, early diagnosis, personalised treatments, and better patient outcomes.
These updates come at a time of significant growth for BrainScope, as the company scales its commercial operations and clinical research efforts.
A new company website has also been launched to highlight the latest deep learning technology and BrainScope’s wider mission in brain health.
With these developments, BrainScope is continuing its mission to transform neurological care through advanced AI and EEG technologies, aiming to improve diagnosis and outcomes for a range of brain conditions.
